TR201902400T4 - Multivalan antijen bağlama Fv molekülü. - Google Patents
Multivalan antijen bağlama Fv molekülü. Download PDFInfo
- Publication number
- TR201902400T4 TR201902400T4 TR2019/02400T TR201902400T TR201902400T4 TR 201902400 T4 TR201902400 T4 TR 201902400T4 TR 2019/02400 T TR2019/02400 T TR 2019/02400T TR 201902400 T TR201902400 T TR 201902400T TR 201902400 T4 TR201902400 T4 TR 201902400T4
- Authority
- TR
- Turkey
- Prior art keywords
- binding molecule
- antigen
- molecule
- antigen binding
- polypeptide
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Bir açıda, mevcut buluş iki polipeptit zincir içeren albumin ve CD3 için spesifik bir antijen bağlama molekülü ile ilgilidir, her bir polipeptit zincir, Fv oluşumunu önleyen bir oryantasyonda en az dört değişken alan içerir ve iki polipeptit zincir birbiri ile dimerize edilir, bu şekilde bir multivalan antijen bağlama molekülü oluşturulur. İki polipeptit zincirin her biri üzerinde, dört değişken alan polipeptitin N-terminalinden C-terminaline V L A-V H B-V L B-V H A sırasında düzenlenir. Antijen bağlama molekülümüm bileşimleri ve çeşitli hastalıkların tedavisine yönelik antijen bağlama molekülünün ve bunun bileşimlerinin kullanılmasına yönelik yöntemler burada sağlanır.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30820510P | 2010-02-25 | 2010-02-25 | |
| EP10154751.1A EP2361936B1 (en) | 2010-02-25 | 2010-02-25 | Antigen-binding molecule and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201902400T4 true TR201902400T4 (tr) | 2019-03-21 |
Family
ID=42232726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/02400T TR201902400T4 (tr) | 2010-02-25 | 2011-02-25 | Multivalan antijen bağlama Fv molekülü. |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP2361936B1 (tr) |
| DK (1) | DK2371866T3 (tr) |
| ES (2) | ES2582001T3 (tr) |
| HR (1) | HRP20190288T1 (tr) |
| HU (1) | HUE041615T2 (tr) |
| LT (2) | LT2361936T (tr) |
| PL (2) | PL2361936T3 (tr) |
| PT (2) | PT2361936T (tr) |
| RS (1) | RS58352B1 (tr) |
| SI (1) | SI2371866T1 (tr) |
| TR (1) | TR201902400T4 (tr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2613368C2 (ru) * | 2011-07-22 | 2017-03-16 | Аффимед Гмбх | Поливалентная антиген-связывающая fv-молекула |
| PT2970449T (pt) * | 2013-03-15 | 2019-11-06 | Amgen Res Munich Gmbh | Moléculas de ligação de cadeia única compreendendo abp n-terminal |
| SG11201609912TA (en) | 2014-05-29 | 2016-12-29 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
| EP3164417A1 (en) | 2014-07-01 | 2017-05-10 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| EP3212232A4 (en) * | 2014-10-31 | 2019-01-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | ANTIBODY BISPECIFIC ANTI-TLR9 |
| KR20170105622A (ko) | 2015-01-26 | 2017-09-19 | 마크로제닉스, 인크. | Dr5-결합 도메인을 포함하는 다가 분자 |
| PT3298033T (pt) | 2015-05-18 | 2020-09-22 | Tcr2 Therapeutics Inc | Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| LT3456346T (lt) | 2015-07-30 | 2021-09-27 | Macrogenics, Inc. | Pd-1 ir lag-3 surišančios molekulės ir jų panaudojimo būdai |
| WO2017106061A1 (en) | 2015-12-14 | 2017-06-22 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
| UY37127A (es) | 2016-02-17 | 2017-08-31 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
| AU2017249435B2 (en) | 2016-04-15 | 2024-05-02 | Macrogenics, Inc. | Novel B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| KR20190058509A (ko) | 2016-10-07 | 2019-05-29 | 티씨알2 테라퓨틱스 인크. | 융합 단백질을 이용하는 t-세포 수용체 리프로그래밍을 위한 조성물 및 방법 |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| BR112019012950A2 (pt) | 2016-12-23 | 2019-11-26 | Macrogenics Inc | molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo |
| JP7115758B2 (ja) | 2017-02-28 | 2022-08-09 | アッフィメッド・ゲー・エム・ベー・ハー | Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ |
| EA201991632A1 (ru) * | 2017-02-28 | 2020-03-12 | Аффимед Гмбх | Комбинация антитела против cd16a с цитокином |
| CA3085432A1 (en) | 2017-12-12 | 2019-06-20 | Macrogenics Inc. | Bispecific cd16-binding molecules and their use in the treatment of disease |
| BR112020016485A2 (pt) | 2018-02-15 | 2020-12-15 | Macrogenics, Inc. | Molécula de ligação, composição farmacêutica e método para o tratamento de uma doença |
| PE20201346A1 (es) | 2018-04-13 | 2020-11-25 | Affimed Gmbh | Constructos de fusion de anticuerpos que se acoplan a celulas nk |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| DE10060140A1 (de) * | 2000-12-04 | 2002-06-06 | Vectron Therapeutics Ag Imt | Multimerer mehrfach-antigenbindender einzelkettiger Antikörper |
| AU2003227504A1 (en) * | 2002-04-15 | 2003-10-27 | Chugai Seiyaku Kabushiki Kaisha | METHOD OF CONSTRUCTING scDb LIBRARY |
| EP1400534B1 (en) | 2002-09-10 | 2015-10-28 | Affimed GmbH | Human CD3-specific antibody with immunosuppressive properties |
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
-
2010
- 2010-02-25 LT LTEP10154751.1T patent/LT2361936T/lt unknown
- 2010-02-25 ES ES10154751.1T patent/ES2582001T3/es active Active
- 2010-02-25 PL PL10154751.1T patent/PL2361936T3/pl unknown
- 2010-02-25 EP EP10154751.1A patent/EP2361936B1/en active Active
- 2010-02-25 PT PT101547511T patent/PT2361936T/pt unknown
-
2011
- 2011-02-25 LT LTEP11156113.0T patent/LT2371866T/lt unknown
- 2011-02-25 HU HUE11156113A patent/HUE041615T2/hu unknown
- 2011-02-25 EP EP11156113.0A patent/EP2371866B1/en active Active
- 2011-02-25 DK DK11156113.0T patent/DK2371866T3/en active
- 2011-02-25 SI SI201131675T patent/SI2371866T1/sl unknown
- 2011-02-25 TR TR2019/02400T patent/TR201902400T4/tr unknown
- 2011-02-25 RS RS20190201A patent/RS58352B1/sr unknown
- 2011-02-25 PL PL11156113T patent/PL2371866T3/pl unknown
- 2011-02-25 PT PT11156113T patent/PT2371866T/pt unknown
- 2011-02-25 ES ES11156113T patent/ES2711377T3/es active Active
-
2019
- 2019-02-13 HR HRP20190288TT patent/HRP20190288T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2582001T3 (es) | 2016-09-08 |
| LT2361936T (lt) | 2016-09-12 |
| PL2361936T3 (pl) | 2016-10-31 |
| DK2371866T3 (en) | 2019-03-18 |
| ES2711377T3 (es) | 2019-05-03 |
| HRP20190288T1 (hr) | 2019-04-05 |
| EP2371866A2 (en) | 2011-10-05 |
| HUE041615T2 (hu) | 2019-05-28 |
| EP2361936B1 (en) | 2016-04-20 |
| RS58352B1 (sr) | 2019-03-29 |
| SI2371866T1 (sl) | 2019-04-30 |
| PT2361936T (pt) | 2016-07-15 |
| EP2371866B1 (en) | 2018-11-21 |
| PL2371866T3 (pl) | 2019-05-31 |
| LT2371866T (lt) | 2019-03-12 |
| EP2371866A3 (en) | 2013-06-26 |
| PT2371866T (pt) | 2019-02-27 |
| EP2361936A1 (en) | 2011-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201902400T4 (tr) | Multivalan antijen bağlama Fv molekülü. | |
| MX347829B (es) | Molécula fv de unión a antígeno multivalente. | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| CY1123518T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
| PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
| CY1121392T1 (el) | Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| RS53042B (en) | ANTIBODIES AGAINST ERBB3 AND THEIR USES | |
| AR111361A1 (es) | Anticuerpos biespecíficos de unión específica a pd1 y lag3 | |
| CO2017011486A2 (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales | |
| EA201791393A2 (ru) | АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ | |
| TR201907397T4 (tr) | Il-15 ve ıl-15 alfa suşi alanı bazlı immünositokinler. | |
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
| UA106607C2 (uk) | Білки специфічного зв'язування і їх застосування | |
| TR201815254T4 (tr) | Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari | |
| AR077111A1 (es) | Proteinas biespecificas tetravalentes de union a antigeno | |
| MX2013001900A (es) | Metodos para la generacion de anticuerpos multiespecificos y multivalentes. | |
| EA202190542A1 (ru) | Сконструированные биспецифические белки | |
| EA201790862A1 (ru) | Связывающиеся с эритроцитами терапевтические средства | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| RU2015147300A (ru) | Гуманизированные антитела к cxcr5, их производные и их применение | |
| EA201390453A1 (ru) | Человеческие анти-тау антитела | |
| RS52782B (en) | HIGH AFINITY HUMAN ANTIBODIES FOR THE HUMAN IL-4 RECEPTOR | |
| UA110358C2 (en) | Molecules of antibody binding il-17a and il-17f |